These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34108728)

  • 1. Daily briefing: Alzheimer's drug controversially approved by FDA.
    Graham F
    Nature; 2021 Jun; ():. PubMed ID: 34108728
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily briefing: Safety review is big step towards the first FDA-approved CRISPR therapy.
    Graham F
    Nature; 2023 Oct; ():. PubMed ID: 37907790
    [No Abstract]   [Full Text] [Related]  

  • 4. Tacrine: first drug approved for Alzheimer's disease.
    Crismon ML
    Ann Pharmacother; 1994 Jun; 28(6):744-51. PubMed ID: 7919566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
    Varadharajan A; Davis AD; Ghosh A; Jagtap T; Xavier A; Menon AJ; Roy D; Gandhi S; Gregor T
    J Neurosci Rural Pract; 2023; 14(4):566-573. PubMed ID: 38059250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.
    Bassil N; Thaipisuttikul P; Grossberg GT
    Expert Opin Pharmacother; 2010 Jul; 11(10):1765-71. PubMed ID: 20540654
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Adebambo K; Ojoh OC
    Int J Alzheimers Dis; 2024; 2024():2988685. PubMed ID: 38371416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily briefing: How an Alzheimer's gene ravages the brain.
    Graham F
    Nature; 2022 Nov; ():. PubMed ID: 36434192
    [No Abstract]   [Full Text] [Related]  

  • 10. Daily briefing: Drugs such as Ozempic could help with Alzheimer's and Parkinson's.
    Graham F
    Nature; 2024 Jan; ():. PubMed ID: 38291330
    [No Abstract]   [Full Text] [Related]  

  • 11. Daily briefing: Abnormal protein levels could be an early hallmark of Alzheimer's disease.
    Graham F
    Nature; 2023 Jul; ():. PubMed ID: 37491413
    [No Abstract]   [Full Text] [Related]  

  • 12. Daily briefing: New evidence supports controversial hypothesis of 'transmissible' Alzheimer's.
    Krämer K
    Nature; 2024 Jan; ():. PubMed ID: 38297051
    [No Abstract]   [Full Text] [Related]  

  • 13. Daily briefing: Alzheimer's makes brain cells undergo 'cellular suicide'.
    Krämer K
    Nature; 2023 Sep; ():. PubMed ID: 37730779
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.
    Bassil N; Grossberg GT
    CNS Drugs; 2009; 23(4):293-307. PubMed ID: 19374459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive COVID-19 Daily News and Medical Literature Briefing to Inform Health Care and Policy in New Mexico: Implementation Study.
    Jarratt L; Situ J; King RD; Montanez Ramos E; Groves H; Ormesher R; Cossé M; Raboff A; Mahajan A; Thompson J; Ko RF; Paltrow-Krulwich S; Price A; Hurwitz AM; CampBell T; Epler LT; Nguyen F; Wolinsky E; Edwards-Fligner M; Lobo J; Rivera D; Langsjoen J; Sloane L; Hendrix I; Munde EO; Onyango CO; Olewe PK; Anyona SB; Yingling AV; Lauve NR; Kumar P; Stoicu S; Nestsiarovich A; Bologa CG; Oprea TI; Tollestrup K; Myers OB; Anixter M; Perkins DJ; Lambert CG
    JMIR Med Educ; 2022 Feb; 8(1):e23845. PubMed ID: 35142625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of medications approved for Alzheimer's disease in autism spectrum disorder: a systematic review.
    Rossignol DA; Frye RE
    Front Pediatr; 2014; 2():87. PubMed ID: 25202686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer's Disease Progression.
    Sharo C; Zhai T; Huang Z
    Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38276010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs.
    Daval CJR; Sarpatwari A; Kesselheim AS
    Health Aff (Millwood); 2022 May; 41(5):713-721. PubMed ID: 35500185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer's Disease.
    Shityakov S; Skorb EV; Förster CY; Dandekar T
    Front Chem; 2021; 9():736509. PubMed ID: 34751244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personal meaningfulness of potential FDA-approved treatments: Perspectives of individuals living with Alzheimer's disease.
    Moreno M; Kline CR; Lanigan K; Kallmyer B; Clifford K; Fazio S
    Alzheimers Dement; 2023 Oct; 19(10):4753-4755. PubMed ID: 37057808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.